Clinical photon-counting CT increases CT number precision and reduces patient size dependence compared to single- and dual- energy CT.

Objectives: To study whether photon-counting computed tomography (PCCT) can improve CT number accuracy, precision and reduce patient size dependence compared to dual-energy CT (DECT) virtual monoenergetic imaging (VMI) and single-energy CT (SECT).

Methods: Clinical PCCT, DECT and SECT scanners were used to image a multi-energy quality assurance phantom and tissue-equivalent inserts with/without an outer nested annulus, representing two object sizes (18 and 33 cm). CT numbers were converted to linear attenuation coefficients (LAC) and regions-of-interest applied.

Optimization of Low-Contrast Detectability in Abdominal Imaging: A Comparative Analysis of PCCT, DECT, and SECT Systems.

Background: Clear representation of anatomy is essential in the assessment of pathology in computed tomography (CT). With the introduction of photon-counting CT (PCCT) and more advanced iterative reconstruction (IR) algorithms into clinical practice, there is potential to improve low-contrast detectability in CT protocols. As such, it is necessary to perform task-based assessments to optimize protocols and compare image quality between PCCT and energy-integrating CT, like dual-energy CT (DECT) and single-energy CT (SECT).

Clinical 7 Tesla magnetic resonance imaging: Impact and patient value in neurological disorders.

Magnetic resonance imaging (MRI) is a cornerstone of non-invasive diagnostics and treatment monitoring, particularly for diseases of the central nervous system. Although 1.5- and 3 Tesla (T) field strengths remain the clinical standard, the advent of 7 T MRI represents a transformative step forward, offering superior spatial resolution, contrast, and sensitivity for visualizing neuroanatomy, metabolism, and function.

Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting.

Predicting amyloid status is crucial in light of upcoming disease-modifying therapies and the need to identify treatment-eligible patients with Alzheimer's disease. In our study, we aimed to predict CSF-amyloid status and eligibility for anti-amyloid treatment in a memory clinic by (I) comparing the performance of visual/automated rating scales and MRI volumetric analysis and (II) combining MRI volumetric data with neuropsychological tests and APOE4 status. Two hundred ninety patients underwent a comprehensive assessment.

[New Alzheimer's treatments - a need for national preparations and coordination].

Approximately 100,000 persons live with Alzheimer's disease in Sweden. As the population ages, the need for diagnostics and disease-modifying treatment grows. Previously available treatments provide moderate symptom relief but do not affect disease progression.